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1-Phenyl-3-(p-substituted
phenyl)-1H-pyrazole-4-
carbaldehydeAbstract A series of 2-(5-chlorobenzo[d]thiazol-2-ylimino)-5-((3-(p-substituted phenyl)-1-phenyl-
1H-pyrazol-4-yl)methylene)thiazolidin-4-ones (3a–h) were prepared from 2-(5-chlorobenzo[d]
thiazol-2-ylimino)thiazolidin-4-one (1) and 1-phenyl-3-(p-substituted phenyl)-1H-pyrazole-4-carb-
aldehyde (2a–h). All compounds were characterized using elemental analytical (C, H, and N) and
spectral (FT-IR, 1H NMR, 13C NMR and GC–MS) data. These compounds were screened for their
antibacterial, antifungal and antimycobacterial activities. Antimicrobial activity was evaluated
against the bacterial strains e.g., Eschericha coli (MTCC 443), Pseudomonas aeruginosa (MTCC
1688), Staphylococcus aureus (MTCC 96), Streptococcus pyogenes (MTCC 442), H37Rv strain of
Mycobacterium tuberculosis, and the antifungal activity was observed against strains e.g., Candida
albicans (MTCC 227), Aspergillus niger (MTCC 282) and Aspergillus clavatus (MTCC 1323). All the
synthesized compounds were found to possess moderate to excellent activity against selected strains.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The widespread use of antifungal and antibacterial drugs and
the fast development of pathogen resistance to most of the
known antibiotics is becoming a serious problem (Chu et al.,
1996). So, it has become quite difﬁcult to eradicate these
microbial infections (Patterson, 2005). Heterocyclic com-
pounds are reported to be effective against many of these
pathogens up to some extent. A heterocyclic compound isone which possesses a cyclic structure with at least two differ-
ent kinds of hetero atoms in the ring and the most common
hetero atoms are nitrogen, oxygen, and sulfur. Heterocyclic
compounds are very widely distributed in nature and are essen-
tial to life as they play a very important role in the metabolism
of many living cells, e.g., amino acids, vitamins, DNA base
(purines and pyrimidines) (Achson, 2009).
Benzothiazole moieties are known to be weak base hetero-
cyclic compounds, having diverse biological activities and are
of great scientiﬁc interest nowadays. They are widely studied
in the areas of bioorganic and medicinal chemistry with many
applications in drug discoveries. Drugs containing benzothia-
zole moiety are reported to possess numerable biological activ-
ities such as antimicrobial (Gupta et al., 2009; Kumbhare and
Ingle, 2009; Lacova et al., 1989; Rajeeva et al., 2009; Maharan
et al., 2007), anticancer (Linhong et al., 2006; Kamal et al.,
2006; Kini et al., 2007; Stanton et al., 2008), anthelmintic
S532 H. B0Bhatt, S. Sharma(Sreenivasa et al., 2009), antidiabetic (Pattan et al., 2005;
Hermenegilda et al., 2008), anti tuberculosis (Abdel-Rahman
and Morsy, 2007; Nandy et al., 2006), antiviral (Shingare et al.,
1996; Mane et al., 1996), as well as antitumor (Yoshida
et al., 2005; Cedric et al., 2006). Predominantly, 4-thiazolidi-
nones are known to possess various important biological
activities such as anti-inﬂammatory (Ottana et al.,2005), anti-
tubercular (Srivastava et al., 2005), antimicrobial (Mistry
and Desai, 2004), anticonvulsant (Kaur et al., 2010), antiviral
(Terzioglu et al., 2006), and anti-HIV (Balzarini et al., 2009).
Besides these compounds, pyrazole derivatives are also associ-
ated with many biologically important activities like antimi-
crobial (Damljanovic et al., 2009), anti-inﬂammatory (Bekhit
et al., 2008), antitubercular (Chovatia et al., 2007), antitumor
(Joksovic et al., 2009), antiangiogenesis (Abadi et al., 2003),
antiparasitic (Rathelot et al., 2002), and antiviral (Hashem
et al., 2007).
Therefore, it is envisaged that chemical entities with benzo-
thiazole, pyrazole and 4-thiazolidinone moieties would result
in compounds of interesting biological activities. In view of
these ﬁndings, we have attempted to incorporate all these three
biologically active components together to give a conﬁned
structure like the titled compounds for evaluating their antimi-
crobial and anti mycobacterial activities.
2. Experimental
2.1. General
The melting points of the products were determined by open
capillary method using Mettler Toledo FP 62 melting point
apparatus (Metter Toledo-Switzerland) and were used without
correction. The FT-IR spectra were recorded on a Perkin El-
mer Spectrum GX FT-IR System (USA) in a KBr disk. 1H
and 13C spectra were recorded on 200 and 500 MHz Bruker
Avance DPX NMR spectrometer using DMSO-d6 as a solvent
and TMS as an internal standard. The mass spectra were re-
corded on a Shimadzu QP2010 spectrometer (equipped with
a direct inlet probe) operated at 70 eV. Elemental analysis
was carried out on Perkin Elmer CHNS (O) analyzer (PE-
2400 Series II-USA). Homogeneity of compounds was checked
by analytical TLC on a silica gel GF 254 plate using ethyl ace-
tate/methanol (10:90) as a solvent system.
2.2. Biological assay
2.2.1. Antibacterial activity
The newly synthesized compounds were screened for their anti-
bacterial activity against gram positive bacteria Staphylococcus
aureus (MTCC-96) and Streptococcus pyogenes (MTCC-442)
and gram negative Escherichia coli (MTCC-443) and Pseudo-
monas aeruginosa (MTCC-1688). Thiazole inhibits protein syn-
thesis in bacteria by binding to the complex formed between
23S rRNA and ribosomal protein L11, thereby restricting
the action of GTP dependent elongation factors (Porse et al.,
1998). Antibacterial activity was carried out by serial broth
dilution method (Ghalem and Mohamed, 2009). The standard
strains used for the antimicrobial activity was procured from
the Institute of Microbial Technology, Chandigarh. The com-
pounds (3a–h) were screened for their antibacterial activity in
triplicate against E. coli, S. aureus, P. aeruginosa, and S. pyog-
enes at different concentrations of 1000, 500, 200, 100, 50, 25,12.5 lg/ml as shown in (Figs. 3 and 4). The growths of bacte-
rial cultures were monitored after 24 and 48 h. The lowest con-
centration, which showed no growth after spot subculture was
considered as MIC for each drug. The highest dilution show-
ing at least 99% inhibition is taken as MIC. The test mixture
should contain 108 cells/ml. The standard drug used was
‘ampicillin’ for evaluating antibacterial activity and it showed
100, 100, 250, and 100 lg/ml MIC against E. coli, P. aerugin-
osa, S. aureus and S. pyogenes, respectively.
2.2.2. Antifungal activity
Same compounds were tested for antifungal activity in tripli-
cate against Candida albicans, Aspergillus niger, and Aspergil-
lus clavatus at various concentrations of 1000, 500, 200, and
100 lg/ml as shown in (Figs. 5 and 6). The results were re-
corded in the form of primary and secondary screening. The
synthesized compounds were diluted at 1000 lg/ml concentra-
tion, as a stock solution. The synthesized compounds which
were found to be active in this primary screening were further
tested in a second set of dilution against all microorganisms.
The lowest concentration, which showed no growth after spot
subculture was considered as MIC for each drug. The highest
dilution showing at least 99% inhibition is taken as MIC and
the test mixture was found to contain 108 spores/ml. ‘‘Griseo-
fulvin’’ was used as a standard drug for antifungal activity and
it recorded 500, 100 and 100 lg/ml MIC for C. albicans, A. ni-
ger, and A. clavatus, respectively.
2.2.3. Antimycobacterial
The screening of antimycobacterial activity of novel synthe-
sized compound was carried out in vitro against a highly
virulent H37Rv strain of Mycobacterium tuberculosis. Antimy-
cobacterial activity was performed as per the LJ Medium (con-
ventional method). The media were incubated for four weeks.
The screening was performed in triplicate at 250 lg/ml concen-
tration of compound. ‘‘Isoniazid’’ was used as a standard drug
for antimycobacterial activity, which showed 0.2 lg/ml MIC
against H37Rv M. tuberculosis strains. The data are as shown
in (Figs. 7 and 8).
2.3. General synthesis method
2.3.1. Synthesis of 2-(5-chlorobenzo[d]thiazol-2-ylimino)
thiazolidin-4-one (1)
The titled compound was prepared according to the method
reported earlier (Ameya and Nandini, 2007). Characterization
data of the compounds matched well with the reported values.
To the cold glacial acetic acid (20 ml), potassium thiocya-
nate (0.08 mol) and 4-chloro aniline (0.01 mol) were added
and mixture was placed in freezing mixture of ice with contin-
uous mechanical stirring. Bromine (1.6 ml) was added at con-
trolled temperature, when all the bromine was added
(105 min), the solution was stirred for 2 h below room temper-
ature and then for 10 h at room temperature, and resultant
mixture was kept for overnight. Yellow precipitate so obtained
was ﬁltered out and the ﬁltrate was neutralized with ammonia
to give 2-amino-6-chloro methyl benzothiazole, which was
further reacted with chloroacetyl chloride and ammonium
thiocyanate to give 2-(5-chlorobenzo[d]thiazol-2-ylimino)thiaz-
olidin-4-one. Product was ﬁltered, washed with water and
recrystallized from glacial acetic acid.
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pyrazole-4-carbaldehydes (2a–h)
The titled compounds were synthesized according to the meth-
od published earlier (Kira et al., 1969; Prakash et al., 2011a;
Prakash et al., 2011b). Characterization data of these com-
pounds matched well with the reported value.
p-Substituted acetophenone (10 mM) on treatment with
phenyl hydrazine (10 mM) produced corresponding Schiff’s
bases. These were added to the chilled formylated solution of
dimethyl formamide (10 ml) and phosphorous oxychloride
(1.3 ml) at 0–5 C with continuous mechanical stirring.
Reaction mixture was poured to ice to get the pyrazole ring
aldehyde. Product was ﬁltered, washed with water and recrys-
tallized from methanol.
2.3.3. 2-(5-Chlorobenzo[d]thiazol-2-ylimino)-5-((3-(p-
substituted phenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)
thiazolidin-4-ones (3a–h)
To a solution of 2-(5-chlorobenzo[d]thiazol-2-ylimino)thiazoli-
din-4-one (1) in ethanol (10 mM) and fused sodium acetate
(10 mM), 1-phenyl-3-(p substituted phenyl)-1H-pyrazole-4-
carbaldehyde (2a–h) (10 mM) was added. The reaction mixture
was heated under reﬂux for 6 h. A bright yellow crystalline
product was formed and the excess solvent was removed under
reduced pressure. Crude product was washed with water, iso-
lated by ﬁltration and re-crystallized from ethanol to yield
compounds (3a–h).2.4. Physical and spectral data
2.4.1. 2-(5-Chlorobenzo[d]thiazol-2-ylimino)-5-((1,3-
diphenyl-1H-pyrazol-4-yl)methylene)thiazolidin-4-one (3a)
Yield 76%; Yellow crystalline solid; mp 139–141 C; IR (KBr,
cm1) m: 3419 (NH– stretching), 3118, 3054 (Ar-H stretching,
pyrazole –H stretching), 1725 (C‚O stretching), 1579, 1499,
1440 (C‚N, C‚C, aromatic ring), 693 (C–S–C linkage),
1332 (C‚S stretching); 1H NMR (DMSO-d6) d (ppm): 8.87
(s,1H,–C‚CH group in pyrazole ring), 8.31–7.41 (m, 15H,
Ar-H, C–NH, –C‚CH); 13C NMR (DMSO-d6) d (ppm):
158.856, 152.616, 138.848, 131.227, 130.911, 129.755,
128.662, 127.904, 127.606, 126.934, 126.807, 126.230,
123.209, 122.230, 119.568, 116.110, 115.939; MS: m/z: 513
(M+), 276, 215,1 72, 147; Anal. Calcd for C26H16ClN5OS2
(513.0) (%): C, 60.75; H, 3.14; N, 13.62; S, 12.48. Found: C,
60.62; H, 3.28; N, 13.62; S, 12.58.2.4.2. 2-(5-Chlorobenzo[d]thiazol-2-ylimino)-5-((1-phenyl-3-
p-tolyl-1H-pyrazol-4-yl)methylene)thiazolidin-4-one (3b)
Yield 81%; Yellow crystalline solid; mp Decomposed; IR
(KBr, cm1) m: 3437 (NH– stretching), 3121, 3057 (Ar-H
stretching, pyrazole –H stretching), 1727 (C‚O stretching),
1579, 1421, 1438 (C‚N, C‚C, aromatic ring), 685 (C–S–C
linkage), 1337 (C‚S stretching); 1H NMR (DMSO-d6) d
(ppm): 8.82 (s, 1H, –C‚CH group in pyrazole ring), 8.05–
7.37 (m, 14H, Ar-H, C–NH, –C‚CH) 2.40 (s, 3H, Ar-CH3
ring); 13C NMR (DMSO-d6) d (ppm): 130.167, 129.030,
127.971, 127.204, 126.291, 122.899, 122.080, 119.838, 21.372;
MS: m/z: 527 (M+), 290, 257, 172, 128; Anal. Calcd for
C27H18ClN5OS2 (527.0) (%): C, 61.41; H, 3.44; N, 13.26; S,
12.14. Found: C, 61.72; H, 3.56; N, 13.55; S, 12.21.2.4.3. 2-(5-Chlorobenzo[d]thiazol-2-ylimino)-5-((3-(4-
hydroxyphenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)
thiazolidin-4-one (3c)
Yield 66%; Yellow crystalline solid; mp Decomposed; IR
(KBr, cm1) m: 3346 (NH– stretching), 3123, 3053 (Ar-H
stretching, pyrazole –H stretching), 1691 (C‚O stretching),
1576, 1480, 1436 (C‚N, C‚C, aromatic ring), 684 (C–S–C
linkage), 1329 (C‚S stretching); 1H NMR (DMSO-d6) d
(ppm): 8.75 (s, 1H, –C‚CH group in pyrazole ring), 8.13–
6.87 (m, 15H, Ar-H, C–NH, –C‚CH); 13C NMR (DMSO-
d6) d (ppm): 167.091, 166.791, 163.586, 161.753, 153.003,
148.893, 138.878, 130.878, 130.132, 129.754, 128.651,
127.874, 127.562, 121.654, 119.518, 116.099, 115.928; MS: m/
z: 529 (M+), 292, 264, 184, 130; Anal. Calcd for
C26H16ClN5O2S2 (529.0) (%): C, 58.92; H, 3.04; N, 13.21; S,
12.10. Found: 58.37; H, 3.12; N, 13.07; S, 12.19.2.4.4. 2-(5-Chlorobenzo[d]thiazol-2-ylimino)-5-((3-(4-
nitrophenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)
thiazolidin-4-one (3d)
Yield 75%; Yellow crystalline solid; mp 267–269 C; IR (KBr,
cm1) m: 3424(NH– stretching), 3129, 3077 (Ar-H stretching,
pyrazole –H stretching), 1726 (C‚O stretching), 1579, 1401,
1437 (C‚N, C‚C, aromatic ring), 686 (C–S–C linkage),
1346 (C‚S stretching); 1H NMR (DMSO-d6) d (ppm): 8.87
(s, 1H, –C‚CH group in pyrazole ring), 8.46–7.45 (m, 14H,
Ar-H, C–NH, –C‚CH); 13C NMR (DMSO-d6) d (ppm):
153.922, 153.382, 151.912, 151.429, 148.638, 147.040,
144.992, 139.117, 135.348, 133.572, 151.815, 131.189,
130.239, 120.382, 124.118, 123.259, 122.193, 120.105; MS: m/
z: 558 (M+), 321, 275, 209, 147; Anal. Calcd for
C26H15ClN6O3S2 (558.0) (%): C, 55.86; H, 2.70; N, 15.03; S,
11.47. Found: C, 55.91; H, 2.89; N, 15.14; S, 11.53.2.4.5. 2-(5-Chlorobenzo[d]thiazol-2-ylimino)-5-((3-(4-
ﬂuorophenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)thiazolidin-
4-one (3e)
Yield 59%; Yellow crystalline solid; mp Decomposed; IR
(KBr, cm1) m: 3437 (NH– stretching), 3029 (Ar-H stretching,
pyrazole –H stretching), 1728 (C‚O stretching), 1592, 1504,
1439 (C‚N, C‚C, aromatic ring), 682 (C–S–C linkage),
1334 (C‚S stretching); 1H NMR (DMSO-d6) d (ppm): 8.86
(s, 1H, –C‚CH group in pyrazole ring), 8.16–7.38 (m, 14H,
Ar-H, C–NH, –C‚CH); 13C NMR (DMSO-d6) d (ppm):
162.242, 153.016, 139.322, 131.340, 130.197, 129.072,
128.406, 123.653, 122.134, 119.988; MS: m/z: 531 (M+), 294,
233, 209, 147; Anal. Calcd for C26H16ClFN5OS2 (531.0) (%):
C, 58.70; H, 2.84; N, 13.16; S, 12.05. Found: C, 58.61; H,
2.67; N, 13.21; S, 12.17.
2.4.6. 2-(5-Chlorobenzo[d]thiazol-2-ylimino)-5-((3-(4-
bromophenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)thiazolidin-
4-one (3f)
Yield 69%; Yellow crystalline solid; mp >300 C; IR (KBr,
cm1) m: 3436 (NH– stretching), 3121, 3055 (Ar-H stretching,
pyrazole –H stretching), 1727 (C‚O stretching), 1592, 1527,
1439 (C‚N, C‚C, aromatic ring), 687 (C–S–C linkage),
1325 (C‚S stretching); 1H NMR (DMSO-d6) d (ppm): 8.87
(s, 1H, –C‚CH group in pyrazole ring), 8.14–7.45 (m, 14H,
Ar-H, C–NH, –C‚CH); 13C NMR (DMSO-d6) d (ppm):
S534 H. B0Bhatt, S. Sharma158.291, 151.947, 138.919, 134.655, 130.090, 129.718, 128.246,
127.381, 126.869, 123.742, 123.168, 122.072, 121.685, 119.408,
115.771; MS: m/z: 591 (M+), 356, 231, 209, 172; Anal. Calcd
for C26H15ClBrN5OS2 (591.0) (%): C, 52.67; H, 2.55; N,
11.81; S, 10.82. Found: C, 52.76; H, 2.63; N, 11.78; S, 10.74.
2.4.7. 2-(5-Chlorobenzo[d]thiazol-2-ylimino)-5-((3-(4-
chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)
thiazolidin-4-one (3g)
Yield 72%; Yellow crystalline solid; mp >300 C; IR (KBr,
cm1) m: 3421 (NH– stretching), 3122, 3060 (Ar-H stretching,
pyrazole –H stretching), 1727 (C‚O stretching), 1584, 1523,
1438 (C‚N, C‚C, aromatic ring), 687 (C–S–C linkage),
1338 (C‚S stretching); 1H NMR (DMSO-d6) d (ppm): 8.88
(s, 1H, –C‚CH group in pyrazole ring), 8.06–7.29 (m, 14H,
Ar-H, C–NH, –C‚CH); 13C NMR (DMSO-d6) d (ppm):
168.193, 138.760, 134.929, 133.119, 129.785, 128.672,
125.720, 125.668, 122.822, 121.743, 119.642, 119.310; MS: m/
z: 531 (M+O), 294, 283, 209, 182; Anal. Calcd for
C26H15Cl2N5OS2 (547.0) (%): C, 56.94; H, 2.76; N, 12.77; S,
11.69. Found: C, 56.75; H, 2.80; N, 12.89; S, 11.79.
2.4.8. 2-(5-Chlorobenzo[d]thiazol-2-ylimino)-5-((3-(4-
methoxyphenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)
thiazolidin-4-one (3h)
Yield 79%; Yellow crystalline solid; mp 250–252 C; IR (KBr,
cm1) m: 3401 (NH– stretching), 3117, 3038 (Ar-H stretching,
pyrazole –H stretching), 1723 (C‚O stretching), 1585, 1524,
1438 (C‚N, C‚C, aromatic ring), 686 (C–S–C linkage),
1321 (C‚S stretching); 1H NMR (DMSO-d6) d (ppm): 8.70
(s, 1H, –C‚CH group in pyrazole ring), 8.11–7.38 (m, 14H,Figure 1 Schematic representation of the synthesis of 2-(5-chlorobe
pyrazol-4-yl)methylene)thiazolidin-4-ones (3a–h).Ar-H, C–NH, –C‚CH), 4.05 (s, 3H, –OCH3 group in pyra-
zole ring); 13C NMR (DMSO-d6) d (ppm): 166.436, 160.019,
153.895, 138.650, 134.125, 130.743, 130.080, 129.577,
129.381, 128.517, 127.545, 123.220, 121.652, 119.430,
115.477, 114,478, 55.290; MS: m/z: 543 (M+), 306, 263, 209,
182; Anal. Calcd for C27H18ClN5O2S2 (543.1) (%): C, 59.61;
H, 3.33; N, 12.87; S, 11.79. Found: C, 59.62; H, 3.41; N,
12.97; S, 11.84.
3. Results and discussion
3.1. Chemistry
In present investigations, we have synthesized and character-
ized the novel 2-(5-chlorobenzo[d]thiazol-2-ylimino)-5-((3-
(p-substituted phenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)
thiazolidin-4-ones (3a–h) derivatives and their antimicrobial
activity was also explored. 6-Chloro-2-benzothiazolamine
was synthesized by interaction of p-chloro aniline with potas-
sium thiocyanate in the presence of bromine and further re-
acted with chloroacetyl chloride and ammonium thiocyanate
to give 2-(5-chlorobenzo[d]thiazol-2-ylimino)thiazolidin-4-one
(1) (Ameya and Nandini, 2007). The ketones on treatment with
phenyl hydrazine yielded corresponding Schiff bases. The
Schiff bases of ketones on treatment with dimethyl formamide
and phosphorous oxychloride undergo cyclization reaction
forming pyrazole derivatives and get formylated onto the pyr-
azole ring (2a–h) (Kira et al., 1969; Prakash et al., 2011a,b).
The ﬁnal compounds 2-(5-chlorobenzo[d]thiazol-2-ylimino)-5-
((3-(p-substituted phenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)
thiazolidin-4-ones (3a–h) were synthesized by the reaction ofnzo[d]thiazol-2-ylimino)-5-((3-(p-substituted phenyl)-1-phenyl-1H-
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Figure 3 Comparative chart of antibacterial activity for com-
pounds (3a–h).
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appropriate 1-phenyl-3-(p-substituted phenyl)-1H-pyrazole-4-
carbaldehyde (Fig. 1). All the synthesized compounds were
characterized by FT-IR, NMR and GC–MS. The IR spectra
of synthesized compounds (3a–h) were assigned expected
bands. The band observed around 1315–1350 cm1 was attrib-
uted to C‚S stretching vibration of thiazole ring. Bands at
about around 1570–1600 cm1 were attributed to C‚N
stretching vibration of pyrazole moiety. Strong bands in the re-
gion 1685–1745 cm1 were due to –C‚O stretching of amide
group. 1H NMR and mass spectral data of compound (3a–h)
are shown in Section 2. Chemical shift d at around 8.9–
8.7 ppm is due to the presence of –C‚CH group in pyrazole
ring. 13C NMR spectra show chemical shift at 21.372 is due
to the presence of –CH3 and chemical shift at 55.290 is due
to the presence of –OCH3 in pyrazole aldehyde. Mass-spectra
data of all the synthesized compounds are in accordance with
its proposed molecular weight. Proposed fragmentation pat-
tern of compound (3d) supports the molecular weight
(Fig. 2). The series of synthesized compounds were subjected
to C, H, and N analyses.
3.2. Antimicrobial activity
Discovery of novel high proﬁle antimicrobial drugs is always in
demand. The process of drugs discovery requires proper scien-
tiﬁc approach, perfect planning and technically designed ef-
fort. Antimicrobial activities of synthesized compound were
performed against four different bacterial strains e.g., E. coli,
P. aeruginosa, S. aureus and S. pyogenes and three different
fungi e.g., C. albicans, A. niger and A. clavatus. Ampicillin,HN
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compounds are presented in (Figs. 3 and 4). For the antibacte-
rial activity, we have selected four different bacterial strainsN
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Figure 4 Comparative chart of antibacterial activity for com-
pounds (1 and 2a–h).
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Figure 6 Comparative chart of antifungal activity for com-
pounds (1 and 2a–h) (*MIC value greater than 1000 lg/ml).
 3a  3b  3c  3d *
S536 H. B0Bhatt, S. Sharmanamely gram negative (E. coli, P. aeruginosa) and gram posi-
tive (S. aureus and S. pyogenes). For antibacterial activity,
compound 3g (R = 4-OCH3) is considered as good active
against E. coli as compared to the standard drug ampicillin,
while compounds 3a (R = 4-H), 3b (R = 4-CH3), and 3f
(R = 4-Br) are considered as moderately active. Compounds
3f (R = 4-Br) and 3g (R = 4-Cl) are moderately active against
P. aeruginosa. Compound 3f (R = 4-Br) is considered as excel-
lently active against S. aureus as compared to the standard
drug ampicillin, while compounds 3a (R = 4-H), 3g (R = 4-
Cl) and 3h (R = 4-OCH3) are considered as good active and
compounds 3b (R = 4-CH3), 3d (R = 4-NO2) and 3e
(R = 4-F) are considered as moderately active. Compound
3f (R = 4-Br) is considered as good active against S. pyogenes
as compared to the standard drug ampicillin, while compounds
3a (R = 4-H), 3g (R = 4-Cl) and 3h (R = 4-OCH3) are con-
sidered as moderately active.C. albicans A. niger A. clavatus
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Figure 5 Comparative chart of antifungal activity for com-
pounds (3a–h) (*MIC value greater than 1000 lg/ml).Among all the synthesized compounds, compound 3f
(R = 4-Br) shows very good activity for all bacterial strains
when compared to parent compound 1 and 2f except in case
of E. coli (Fig. 9). However, the other synthesized compounds
showed speciﬁcity for particular microbial strain and thereby
revealed random distribution pattern of inhibition potential
when compared to their parental compound.
3.2.2. Antifungal activity
Antifungal screening of data of newly synthesized compounds
is as per (Figs. 5 and 6). For the antifungal activity, we have
taken three different fungal strains like C. albicans, A. niger,
and A. clavatus. For antifungal activity, it has been observed
that compounds 3e (R = 4-F) and 3g (R = 4-Cl) are foundH37Rv
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Figure 7 Comparative chart of antimycobacterial activity for
compounds (3a–h) (*99% Inhibition at 0.2 lg/ml concentration of
isoniazid and all the compounds were screened at 250 lg/ml
concentration).
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Figure 8 Comparative chart of antimycobacterial activity for
compounds (1 and 2a–h) (*99% Inhibition at 0.2 lg/ml concen-
tration of isoniazid and all the compounds were screened at
250 lg/ml concentration).
E.C. P.A. S.A. S.P. C.A A.N. A.C
0
200
400
600
800
1000
M
IC
(m
g/
m
L)
Bacterial and fungal Strains
 1
 3f
 2f
Figure 9 Comparative chart of antibacterial and anti fungal
activity for compounds (1, 2f and 3f).
2-(5-Chlorobenzo[d]thiazol-2-ylimino)thiazolidin-4-one derivatives as an antimicrobial agent S537to be excellent active against C. albicans as compared to the
standard drug griseofulvin, while compounds 3d (R = 4-
NO2) and 3f (R = 4-Br) are considered as very good active
and compound 3c (R = 4-OH) is considered as good active.
Among all the synthesized compounds, compound 3f
(R = 4-Br) shows very good activity for all fungal strains com-
pared to parent compounds 1 and 2f (Fig. 9).
3.2.3. Antimycobacterial activity
The results of antimycobacterial screening of the synthesized
compounds are presented in (Figs. 7 and 8). For the anti tuber-
culosis activity, we have taken highly virulent H37RV strain of
M. tuberculosis. Compounds 3a (R = 4-H) and 3e (R = 4-F)
possess good antimycobacterial activity and other compounds
like, 3b (R = 4-CH3), 3c (R = 4-OH), 3d (R = 4-NO2), 3f(R = 4-Br), 3g (R = 4-Cl) and 3h (R = 4-OCH3) possess
poor antimycobacterial activity.
4. Conclusion
A series of 2-(5-chlorobenzo[d]thiazol-2-ylimino)-5-((3-(p-sub-
stituted phenyl)-1-phenyl-1H-pyrazol-yl)methylene)thiazolidin
-4-ones (3a–h) were synthesized from 2-(5-chlorobenzo[d]
thiazol-2-ylimino)thiazolidin-4-one (1) and 1-phenyl-3-(p-sub-
stituted phenyl)-1H-pyrazole-4-carbaldehydes (2a–h). Analyti-
cal and spectral data (FT-IR, 1H NMR, 13C NMR, GC–MS)
of all the synthesized compounds were in good agreement with
the proposed structure. Comparison of the antimicrobial re-
sults of synthesized compounds (3a–h) has revealed that the
addition of pyrazole derivatives in 2-(5-chlorobenzo[d]thia-
zol-2-ylimino)thiazolidin-4-one (1) has improved their antimi-
crobial activity. Most of the compounds were found to be
active against tested microorganisms. A series of 2-(5-chloro-
benzo[d]thiazol-2-ylimino)-5-((3-(p-substitutedphenyl)-1-phenyl
-1H-pyrazol-yl)methylene)thiazolidin-4-ones (3a–h) exhibited
moderate to excellent antibacterial, antifungal and antimyco-
bacterial activities.Acknowledgment
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